Tag Archives: San Diego

RESI San Diego: Family Office Investors Discuss Strategy and What Makes Them Different

20 Jul

By Cole Bunn, Senior Research Analyst, LSN

cole-wp

As the RESI San Diego event is now in the rearview mirror and we prepare to bring RESI home to Boston (Sept. 26th), we wanted to take a closer look at the Medtech Family Office panel session. Family offices are clearly a highly sought-after investor class and are not completely understood by a large portion of entrepreneurs. To that end, we’ve pulled out some of the most insightful points that were discussed and distilled the panel session into this summary video to help shed some light on how family offices evaluate early-stage investments, how to reach them and what differentiates them from VCs and other early-stage investors.

Family offices are not a silver bullet for your financing needs

A lot of entrepreneurs mistakenly believe that finding a family office will solve all their fundraising woes i.e. long-term investors with less rigid requirements. While it is true that family offices tend to be more patient capital and more flexible with terms and deal structures (a result of not having to answer to LPs), these groups are in fact looking for a return and typically will be active either at the board or management level to hit milestones and create value. Additionally, as your company grows and matures, the capital requirements and expertise required for the healthcare space oftentimes necessitate bringing in deep-pocketed institutional investors, who family offices maintain relationships with.

Family offices are purposefully low visibility

Given that family office investors have no mandate or timeline to allocate money, they can wait on the best deals and entrepreneurs to surface, therefore their deal sourcing channels are much different than a VC or another institutional investor. Further, these groups tend to be very much relationship-oriented. Networking is a must to uncover these investors and begin building a relationship, with some of the best events to attend being a part of universities and tech transfer offices as well as focused partnering conferences, such as the RESI conference.

Family offices are not homogenous

This point can’t be stressed enough. While there are some common themes among these groups (mostly dictated by structure or lack thereof), they are largely very different. Some may be more philanthropically motivated as they are looking to fund research/companies pursuing indications that have afflicted their family while others act more like an institutional fund with a focus on returns. It is essential to do as much research as possible on each specific family office to try and find mutual connections and the best way to approach them.

Moderated by Michael Quigley, VP of Investor Research, LSN, the panel includes the following speakers:

  • Sean Kearny, Managing Director, Three Leaf Ventures
  • Kyle Williams, President, Bootstrap Incubation
  • John Kinzell, Sr. Life Science Analyst, The McNair Group
  • Julia Belaya, Director – Corporate Partnerships, Plug & Play Tech Center

RESI San Diego 2017 Innovation Challenge – Winners Announced

22 Jun

By Nono Hu, Director of Marketing, LSN

On June 19, more than 600 healthcare entrepreneurs and investors entered the exhibition hall at the Westin San Diego Gaslamp Quarter. They were greeted by 30 Innovation Challenge finalists across therapeutics, medical device, diagnostics, and healthcare IT sectors. The 30 companies, hand selected by LSN’s scientific and commercial review team, competed directly on merits of innovation and commercial viability. Here, LSN would like to present the top 3 winners who attracted the greatest amount of “RESI Cash”.

First Place: Taithera

Taithera is redefining orthopaedics. Taithera is developing a first-in-class bone targeted drug delivery platform for the treatment of musculoskeletal disorders. The core of Taithera’s revolutionary platform is a nanoparticle that is programmed to deliver therapeutics directly to the site of a bone lesion. This hyper-targeted delivery platform can be used to treat primary and metastatic bone cancers, fractures, osteoporosis, and other bone conditions. Taithera is based in New York City, and was founded by Mo Chen, PhD and Seth Harlem.

Michael Quigley, VP of Market Research, Life Science Nation | Mo Chen, Co-Founder & Chief Science Officer, Taithera | Seth Harlem, Co-Founder & Chief Executive Officer, Taithera

Second Place: Tasso

Tasso is a medical device company that is developing the HemoLink, a user-friendly way to self-collect blood for clinical testing that has the potential to fundamentally change how people interface with healthcare. The HemoLink is a device that enables high-quality blood sample collection with one press of a button. After the blood draw is complete, the tube appended to the device simply twists off and can be used directly within standard lab processes. The HemoLink is enabled by novel microfluidic technologies that enable connectivity (e.g. tube types), simple low-cost manufacturing, and plasma separation onsite. The HemoLink can replace phlebotomy in small clinics and bring blood collection to the home.

Michael Quigley, VP of Market Research, Life Science Nation | Ben Casaavant, VP, Engineering, Tasso

Third Place: ViewsIQ

ViewsIQ is a medical technology company, digitizing patient samples microscopically to disrupt the pathology practice – the last remaining medical imaging field to go digital. ViewsIQ’s Panoptiq system is the first software-based approach to digital imaging that allows seamless integration into a Pathologist’s clinical workflow. With Panoptiq, the cost barrier to digital imaging has been removed, permitting clinicians to offer expert diagnostic care to patients virtually anywhere in the world.

Michael Quigley, VP of Market Research, Life Science Nation | Herman Lo, CEO, ViewsIQ

Thank you to all who competed in the RESI San Diego Innovation Challenge, and to all the RESI attendees who took part by investing their votes in their favorite competing companies.

New at RESI San Diego: Genomics Investors in the Spotlight

15 Jun

By Lucy Parkinson, Director of Research, LSN

Genomic innovation cuts across many technology verticals.  The dawn of efficient and inexpensive gene sequencing enabled many breakthrough discoveries in biology by identifying genes that have a role in specific diseases. Patients can now be stratified by genetic subtypes in order to identify the most suitable treatment. Some startups aim to use sequencing to identify future health risks. Meanwhile, sequencing has created massive amounts of genetic data, which could yield many further discoveries with the right curation and analysis.

At RESI, a panel of investors with a focus on genomics will discuss what kind of breakthroughs they are looking to back, and what challenges still remain in the genomics field.

Moderated by Amanda Cashin (Head of Illumina Accelerator), the participants are:

%d bloggers like this: